Jay Duker serves as the President and Chief Executive Officer at EYEPOINT PHARMACEUTICALS INC, a specialty pharmaceutical company focused on developing and commercializing treatments for eye diseases. With a robust background in ophthalmology and medical technology, Duker has been instrumental in steering the company towards innovation and growth. He joined Eyepoint Pharmaceuticals in 2016, bringing with him extensive experience from his prior roles in the medical field, including his tenure as a Professor of Ophthalmology at Tufts University School of Medicine and his work as a practicing retina specialist. Under Duker's leadership, Eyepoint Pharmaceuticals has seen significant advancements in its product pipeline, particularly with the development of sustained-release treatments for retinal diseases. One of his notable achievements includes the successful FDA approval and subsequent launch of YUTIQ®, a long-term treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. His strategic vision has also led to the expansion of the company’s research and development efforts, positioning Eyepoint as a leader in the ophthalmic pharmaceutical industry. Duker's role involves overseeing the company’s overall operations, driving business development, and ensuring that Eyepoint continues to meet the needs of patients suffering from debilitating eye conditions. In addition to his executive responsibilities, Jay Duker is recognized for his contributions to the field of ophthalmology through his numerous publications and presentations at international conferences. His commitment to advancing medical science is evident in his active involvement in clinical research and his efforts to foster collaborations with other industry leaders. As CEO, Duker continues to lead Eyepoint Pharmaceuticals with a focus on innovation, patient care, and sustainable growth, solidifying the company's reputation as a key player in the development of novel ocular therapies.